Cleveland Clinic, Cleveland, OH, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Oncologist. 2022 Oct 1;27(10):864-873. doi: 10.1093/oncolo/oyac137.
The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV.
We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients.
Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (21.8%) with undetectable CD30 by IHC. No significant differences were observed for any study in overall response rates between patients with CD30 expression ≥10% or <10%. Median duration of response was also similar in the CD30 ≥10% and <10% groups for all studies.
In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain.
靶向 CD30 抗原的抗体药物偶联物 Brentuximab vedotin（BV）在几项外周 T 细胞淋巴瘤（PTCL）、皮肤 T 细胞淋巴瘤（CTCL）或 B 细胞非霍奇金淋巴瘤（NHL）患者的临床试验中已得到评估。本研究旨在探讨 CD30 表达水平与 BV 临床反应之间的关系。
我们分析了 5 项前瞻性临床研究中接受 BV 单药治疗的复发或难治性 PTCL、CTCL 或 B 细胞 NHL 患者的反应。使用 Ber H2 抗体通过免疫组织化学（IHC）评估 CD30 表达，共分析了 275 例患者。
在所有 5 项研究中，140 例（50.9%）患者的肿瘤 CD30 表达<10%，包括 60 例（21.8%）IHC 检测不到 CD30。在任何一项研究中，CD30 表达≥10%或<10%的患者的总缓解率均无显著差异。所有研究中，CD30≥10%和<10%组的中位缓解持续时间也相似。
在这项对一系列 CD30 表达淋巴瘤的研究分析中，单独通过标准 IHC 测量的 CD30 表达并不能预测 BV 的临床获益，因此表达水平的阈值确定不确定。
